peptide elongation factor 2 has been researched along with Depressive Disorder in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cubała, WJ; Gałuszko-Węgielnik, M; Górska, N; Jakuszkowiak-Wojten, K; Szarmach, J; Szałach, ŁP; Słupski, J; Wiglusz, MS; Wilkowska, A; Włodarczyk, A | 1 |
1 other study(ies) available for peptide elongation factor 2 and Depressive Disorder
| Article | Year |
|---|---|
Magnesium and ketamine in the treatment of depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Humans; Ketamine; Magnesium; Peptide Elongation Factor 2; Receptors, N-Methyl-D-Aspartate | 2019 |